Results 131 to 140 of about 9,895 (222)

Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases

Scientific Reports
The purpose of this study was to develop and validate a physiologically based pharmacokinetic (PBPK) model combined with an EGFR occupancy (EO) model for osimertinib (OSI) to predict plasma trough concentration (Ctrough) and the intracranial time-course ...
Feng Liang, Yimei Zhang, Qian Xue, Xiaoling Zhang   +3 more
doaj   +1 more source

Differential Impact of Pharmacokinetic and Pharmacodynamic Variability on Response to Combination Therapy

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso, Ronald Kadada Karyaburo, Jackson K. Mukonzo, Ene I. Ette   +3 more
wiley   +1 more source

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2203-2211, July 2026.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres, Justyna Wozniak, Hannah Fölsch, Anja Knueppel‐Ruppert, Verena Graeff, Andrea Kriegisch‐Stumpf, Harald Dormann, Julia C. Stingl, Katja S. Just   +8 more
wiley   +1 more source

PBPK-modell av oxikodon [PDF]

Bakgrund: Oxikodon syntetiserades år 1916 och togs i klinisk användning ett år senare. Eftersom den aktiva läkemedelsingrediensen utvecklades för så länge sedan, genomgick den inte samma godkännandeprocess som behövs idag.
Kosunen-Koskivaara, Suvi
core  

Advances in Human Mass Balance Studies: An IQ Consortium Perspective on Current Practices and Emerging Trends

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 43-54, July 2026.
Human radiolabeled mass balance studies are crucial for comprehensively characterizing the absorption, distribution, metabolism, and excretion (ADME) of investigational drugs, providing essential data for drug development, regulatory evaluation, and product labeling.
Jason Boer, Ellen Cannady, Filip Cuyckens, Ulrike Glaenzel, Camille Granvil, Felix Huth, Alexander D. James, Wenying Li, Céline Veau, Graeme Young, Qin Yue, Gregory S. Walker, Upendra A. Argikar, Jonathan N. Bauman, Cathy Cantalloube, Yu‐Luan Chen, Ping Kang, Patricia Moliner, Mette L. Pedersen, Isabel Piel, Simone Schadt, Hanno Schieferstein, Julia Suchomel, Shuai Wang, S. Cyrus Khojasteh   +24 more
wiley   +1 more source

Stereoselective Biotransformation: Transfer of Learning to Advance Drug Metabolism and Biocatalysis

Angewandte Chemie, Volume 138, Issue 25, 15 June 2026.
Understanding stereoselective biotransformations has implications for predicting drug disposition and response and may also inspire novel biocatalytic and biomimetic strategies to address challenges in metabolite and API synthesis. ABSTRACT Chirality is an important determinant of drug action, as enantiomers can exhibit markedly different ...
Grace A. Okunlola, Godwin A. Aleku
wiley   +2 more sources

A tutorial on physiologically based pharmacokinetic approaches in lactation research

CPT: Pharmacometrics & Systems Pharmacology
In breastfeeding mothers, managing medical conditions presents unique challenges, particularly concerning medication use and breastfeeding practices.
Amita Pansari, Xian Pan, Lisa M. Almond, Karen Rowland‐Yeo   +3 more
doaj   +1 more source

Integrated PBPK modelling for PFOA exposure and risk assessment

Environmental Research
Per- and polyfluoroalkyl substances (PFASs) pose significant public health concerns due to their environmental persistence, bioaccumulation, and ubiquitous presence in human biomonitoring (HBM) data, despite regulatory restrictions. This study establishes a deterministic pharmacokinetic model for perfluorooctanoic acid (PFOA), enabling the estimation ...
Achilleas Karakoltzidis, Spyros P. Karakitsios, Catherine Gabriel, Dimosthenis Α. Sarigiannis   +3 more
openaire   +3 more sources

EuroMix PBPK model for combined exposures

, 2019
In this paper documents the structure and default parameter values of the EuroMix PBPK model implemented in the MCRA platform for rats and humans. A version allowing apportionment of results by exposure routes is also described. Finally, the extensions needed to describe pharmacokinetic interactions between pairs or triplets of substance are discussed.
Bois, F.Y., Tebby, C., Brochot, C.
openaire   +2 more sources

Butorphanol Pharmacokinetics Across Species: Meta‐Analysis Integrating Allometric Scaling and Minimal Physiologically Based Pharmacokinetic Modeling

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 7, July 2026.
mPBPK Allometric Meta‐Analysis (MAMA) of Butorphanol Across 13 Species. ABSTRACT Butorphanol, an opioid agonist–antagonist used in human and veterinary medicine, lacks systematic interspecies comparisons. Butorphanol pharmacokinetics (PK) was assessed across species using a minimal physiologically based PK (mPBPK) model and allometric scaling, termed ...
Ahmed M. Saeed, William J. Jusko
wiley   +1 more source